STOCK TITAN
  1. Home
  2. Sec-filings
  3. NUS
  4. [8-K] NU SKIN ENTERPRISES, INC. Reports Material Event

Nu Skin (NYSE: NUS) global sales head steps aside for medical leave

Filing Impact
(Moderate)
Filing Sentiment
(Neutral)
Form Type
8-K

Rhea-AI Filing Summary

Nu Skin Enterprises, Inc. (NUS) reported that Justin Keisel, its Executive Vice President and President of Global Sales, began a medical leave of absence effective August 17, 2026. During his absence, Executive Vice President, Chief Operating Officer and Chief Legal Officer Chayce Clark will lead Mr. Keisel’s organization.

The company expresses support for Mr. Keisel as he focuses on his health. No changes to other executive roles or broader strategic initiatives are described in this report.

Positive

  • None.

Negative

  • None.
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers Governance
Key personnel changes including departures, elections, or appointments of directors and executive officers.
medical leave of absence other
"began a medical leave of absence"
Executive Vice President financial
"Justin Keisel, the Executive Vice President and President of Global Sales"
An executive vice president is a high-ranking leader within a company who oversees major parts of its operations or strategies. Think of them as senior managers responsible for important areas, similar to a vice principal in a school hierarchy. Their role matters to investors because they help guide the company's success and decision-making at the top level.
Chief Operating Officer financial
"Executive Vice President, Chief Operating Officer and Chief Legal Officer"
A chief operating officer (COO) is a senior executive responsible for overseeing the day-to-day activities of a company, ensuring that all parts of the organization work smoothly and efficiently. They often act like a company's operational quarterback, translating strategic plans into practical actions. For investors, the COO's effectiveness can influence a company's performance and stability, making them an important figure in assessing the company's management strength.

FAQ

What did Nu Skin Enterprises (NUS) announce in this Form 8-K?
Nu Skin Enterprises (NUS) announced that Executive Vice President and President of Global Sales Justin Keisel began a medical leave of absence effective August 17, 2026, and that his organization will be led by Executive Vice President, COO and CLO Chayce Clark during his absence.

Which Nu Skin (NUS) executive is taking a medical leave of absence?
The executive taking a medical leave of absence is Justin Keisel, who serves as Executive Vice President and President of Global Sales of Nu Skin Enterprises, Inc.

When did the medical leave for Nu Skin (NUS) executive Justin Keisel become effective?
The medical leave of absence for Nu Skin (NUS) executive Justin Keisel became effective on August 17, 2026, according to the company’s current report.

Who will lead the Global Sales organization at Nu Skin (NUS) during Justin Keisel’s leave?
During Justin Keisel’s medical leave, his organization will be led by Chayce Clark, Nu Skin’s Executive Vice President, Chief Operating Officer and Chief Legal Officer.

Does Nu Skin (NUS) describe any other executive changes in this disclosure?
No. The disclosure only states that Justin Keisel is on medical leave and that Chayce Clark will lead his organization. It does not describe any additional executive changes.

Who signed this Nu Skin (NUS) report and in what capacity?
The report was signed on behalf of Nu Skin Enterprises, Inc. by Chelsea K. Lantz, who is identified as the company’s Chief Financial Officer.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Understanding 8-K Material Events →
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 8-K

CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

 
August 17, 2026
  
 
Date of Report (Date of earliest event reported)
 
     
 
NU SKIN ENTERPRISES, INC.
  
 
(Exact name of registrant as specified in its charter)
 

Delaware
  
001-12421
   87-0565309
(State or other jurisdiction of incorporation)
  
(Commission File Number)
 
(IRS Employer Identification Number)

 
75 West Center Street
Provo, Utah 84601
  
 
(Address of principal executive offices and zip code)
 
     
 
(801) 345-1000
  
 
(Registrant’s telephone number, including area code)
 
     
 
N/A
  
 
(Former name or former address, if changed since last report)
  

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
 
☐
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 
☐
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 
☐
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 
☐
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4 (c))
 
Securities registered pursuant to Section 12(b) of the Act:
 
Title of each class
Trading Symbol(s)
Name of each exchange on which registered
Class A Common Stock, $.001 par value
 NUS
New York Stock Exchange

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
 
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 5.02
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

Effective August 17, 2026, Justin Keisel, the Executive Vice President and President of Global Sales of Nu Skin Enterprises, Inc. (the “Company” or “we”), began a medical leave of absence. Chayce Clark, the Company’s Executive Vice President, Chief Operating Officer and Chief Legal Officer, will lead Mr. Keisel’s organization during his time away. We wish Mr. Keisel and his family all the best as he focuses on his health.

SIGNATURE
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
 
 
NU SKIN ENTERPRISES, INC.
 
(Registrant)
   
 
/s/ Chelsea K. Lantz
  
 
Chelsea K. Lantz
 
Chief Financial Officer
   
Date: August 21, 2026
  

 

Source: View Original Filing on SEC EDGAR

Filing Exhibits & Attachments

3 documents

Other Documents